Patent Licensing Types

Grant clause

Defines the patent(s) licensed, the scope (exclusive/non-exclusive), field-of-use, geographic territory, and term. Ambiguity here = expensive disputes.

Royalty provisions

Running royalties (% of sales), lump-sum, milestone payments, minimum annual royalties, royalty stacking credits, and audit rights.

Sublicensing rights

Whether the licensee can sublicense and under what conditions. Include upstream payment obligation and notification requirements.

Improvement and grant-back

Does the licensee's improvement belong to the licensor? Non-exclusive grant-backs are generally acceptable; exclusive grant-backs can raise antitrust concerns.

Enforcement obligations

Who must sue infringers? Who bears the cost? How are recoveries split? For exclusive licensees, failure to enforce can erode the commercial value.

Most-favored-nation (MFN)

Licensor must offer licensee terms at least as favorable as any subsequent licensee. Often negotiated away in exchange for early-mover economics.

Termination

Events of default (non-payment, bankruptcy, breach, change of control), cure periods, and effect of termination on sublicenses.

Representations and warranties

Licensor's ownership, authority to license, no prior conflicting licenses. 'AS IS' disclaimers and liability caps.

What is the difference between an exclusive and a non-exclusive patent license?

An exclusive license grants the licensee the sole right to use the licensed patent within the defined scope — no one else, including the patent owner, can use those rights in that field. An exclusive licensee typically has standing to sue infringers independently. A non-exclusive license grants the same rights to the licensee but allows the patent owner to simultaneously license the same rights to other parties. Non-exclusive licensees generally cannot sue infringers without joining the patent owner. Royalty rates are almost always higher for exclusive licenses because the licensee is paying for exclusivity — for market protection, not just permission. A 'sole' license is a middle ground: only one licensee, but the patent owner retains the right to use the patent themselves.

What is a field-of-use patent license?

A field-of-use license restricts the licensee's rights to a specific application, market vertical, geography, or technology domain. For example, a pharmaceutical company might license a chemical patent exclusively for use in human therapeutics but not for veterinary, agricultural, or industrial applications — those fields remain available for the patent owner or other licensees. Field-of-use restrictions are one of the most common ways patent owners maximize value: they can grant exclusive rights in multiple fields to multiple exclusive licensees simultaneously, without any one licensee having a monopoly over the entire patent. The Supreme Court upheld field-of-use restrictions in Mallinckrodt, Inc. v. Medipart, Inc. (Fed. Cir. 1992). Field-of-use restrictions must be clearly defined in the license — vague field definitions lead to disputes about whether a licensee's new product falls within the licensed scope.

What is a cross-license agreement?

A cross-license is an agreement between two parties where each grants the other a license to their respective patents — typically without cash payment (though 'balancing payments' are common when one party's portfolio is stronger). Cross-licenses are common in industries where companies cannot build products without infringing competitors' patents (semiconductors, smartphones, wireless standards). The structure allows both companies to operate freely without constant litigation. Cross-licenses typically cover the current patent portfolio plus improvements filed during the term (a 'future-granted patent' clause). Key negotiation issues: which specific patents are included, whether the license is bilateral and royalty-free or involves balancing payments, whether it covers only the two companies or extends to their subsidiaries, and what happens to the cross-license if one company is acquired.

What does FRAND mean in patent licensing?

FRAND stands for Fair, Reasonable, and Non-Discriminatory licensing terms. When a patent is declared essential to a technical standard (a standard essential patent or SEP), the patent holder typically commits to licensing it on FRAND terms as a condition of having the patent incorporated into the standard. 'Fair and reasonable' means the royalty rate must reflect a reasonable return on the invention's contribution — courts use the ex ante value of the invention (its value before the standard was adopted, not the lock-in value after), often applying the smallest saleable patent-practicing unit (SSPPU) methodology (Ericsson v. D-Link, Fed. Cir. 2014). 'Non-discriminatory' means similarly situated licensees must be offered comparable terms. FRAND disputes are common — royalty rate litigation can span years and billions of dollars.

What is a compulsory license and when can a government grant one?

A compulsory license is a government-issued authorization for a third party to use a patented invention without the patent owner's consent, usually in exchange for reasonable compensation. Under the TRIPS Agreement (WTO), member countries can grant compulsory licenses in national emergencies, public non-commercial use, anti-competitive purposes, and dependent patent situations. In practice, most compulsory licenses are granted for pharmaceutical patents during public health crises — countries have invoked this right for HIV/AIDS medications (Brazil, Thailand), COVID-19 vaccines, and cancer drugs. In the US, compulsory patent licenses are rarely granted but can arise in antitrust settlements and government use (28 U.S.C. § 1498 allows the US government to use any patent without the owner's consent, with reasonable compensation). The threat of compulsory licensing is sometimes used as negotiating leverage.